


Phenotypic precision approach improves outcomes in patients with very high risk acute lymphoblastic leukaemia

Jasmeet Sidhu

25.09.24




Affiliations

Tata Translational Cancer Research Centre
Tata Medical Center
Kolkata
India





Disclosures

None

High throughput screening for single and combination of drugs







ZIP synergy score: 27.104



Change in drug response (delta area under curve)




<https://synergyfinder.fimm.fi/>

Alternate sensitive synergistic compounds identified for refractory patients



DRP informed therapy significantly improves MRD response and event free survival

Inclusion Criteria	Modification	Treatment block
Hypodiploid <i>TCF3::HLF1</i>	Addition of Venetoclax and Bortezomib (PATH)	Delayed intensification
<i>IKZF1</i> plus with EOI MRD $\geq 10^{-4}$		
EOC MRD $\geq 10^{-4}$		
EO-IM MRD $\geq 10^{-4}$ in frontline EOC MRD $\geq 10^{-4}$ in relapse	Addition of Venetoclax + Bortezomib \pm Selinexor based on DRP (PATHplus)	3 rd block (intensification)
Very Early Relapse* Second relapse		As induction



Toxicity grade	Standard intensification		Modified intensification		p
N	34		25		
NCI-CTCAE	n	%	n	%	
Grade 3	17	50	18	72	0.112
Grade 4	3	9	4	16	0.443
Grade 5	0	0	0	0	1.000

Poster #5
September 25, 18:30 – 19:30